Form 4: Fairmount Funds Management LLC and Tomas Kiselak Report Beneficial Ownership Changes in Dianthus Therapeutics, Inc.

Fairmount Funds Management LLC and Tomas Kiselak report acquisition of stock options in Dianthus Therapeutics, Inc.

Summary

• Fairmount Funds Management LLC and Tomas Kiselak filed a Form 4 detailing changes in beneficial ownership of Dianthus Therapeutics, Inc. (DNTH) securities.
• The report indicates that on May 23, 2024, Fairmount Funds Management LLC acquired 11,000 stock options with an exercise price of $21.77.
• These options vest on the earlier of the first anniversary of the grant date or the Issuer's 2025 Annual Meeting of Stockholders, contingent on Tomas Kiselak's continued service.
• Tomas Kiselak, a Managing Member of Fairmount, disclaims beneficial ownership of the options, as he holds them for investment vehicles managed by Fairmount.
• Fairmount disclaims beneficial ownership except to the extent of its pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Management Comments

• Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund.
• Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock.
• Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therin.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders, including directors and significant shareholders.

Key Dates